Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

Alan Winston; Anton Pozniak; Nicola Smith; Carl Fletcher; Sundhiya Mandalia; Darmishta Parmar; Sarah Gibbons; David Back; Brian Gazzard; Mark Nelson

doi:10.1097/00002030-200402200-00029

Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

Identifier:nobleid.org/w1/20260515/5DBF0CB2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/5DBF0CB2.svg?ark=w1%2F20260515%2F5DBF0CB2)](https://nobleid.org/work/w1/20260515/5DBF0CB2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

Identifier:nobleid.org/w1/20260515/5DBF0CB2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/5DBF0CB2.svg?ark=w1%2F20260515%2F5DBF0CB2)](https://nobleid.org/work/w1/20260515/5DBF0CB2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work